A study published in The Journal of Endocrinology showed the association between the altered levels of the reproductive hormone in mouse modern of obesity can be restored by reducing blood glucose levels. Several studies have highlighted the need for effective therapy in obese women facing fertility issues due to imbalance in reproductive hormones. Hence, the development of an effective therapy that treats obesity along with metabolic health is a major advancement in the field of medicine.

Dapagliflozin is a common drug used to treat type 2 diabetes, where it reduces blood glucose levels and has a positive effect on other metabolic health factors. In the study, the researchers investigated the effect of Dapagliflozin on metabolic health and reproductive hormones in mouse models of obesity. After 8 weeks of application, blood glucose levels, BMI, and reproductive cycles were normalized with the hormone imbalance and ovulation restored in comparison to non-treated mice.

Professor Chen, the lead researcher stated that normalized blood glucose metabolism with dapagliflozin in obese mice is a promising development toward restoring reproductive functions. However, further examination is needed to understand the therapeutic benefits, target molecules, molecular pathways involved, etc. to better treat fertility issues among women. 

(Source: https://www.hindustantimes.com/lifestyle/health/research-correcting-blood-sugar-levels-can-improve-obesity-related-fertility-issues-101653539743483.html )